Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
losartan potassium (+) hydrochlorothiazide combination will be titrated upwards according to the following scheme: losartan potassium 50/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 25
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
50 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
ACEi or ARB naive or not taking ACEi or ARB concurrently for at least one month before the run-in period
Be able to carry out his or her own daily activity
- Be at least 50 years old at inclusion in the study Be diagnosed with mild to moderate hypertension, treated or untreated
Not taking any cognitive-enhanced agent at baseline
Present with a memory complain ( spontaneous or informed by caregiver)
Congestive heart failure with NYHA class >2
Renal failure or renal insufficiency with serum creatinine >1.4mg/dl
chronic severe liver disease with abnormal GPT and GOT >2 times of upper normal limits
Diagnosed with major depression when entering the study
Foreign language as his or her mother tongue so that the test results will not be reliable
History of stroke or transient ischemic attack (stroke is defined as focal neurological sign progressing stepwise)
Hypersensitive to the active ingredient and any other component of losartan potassium and indapamide tablets
Major hearing loss/deafness and/or major visual impairment/blindness preventing from performing the tests